- Citations, last 5 years
- 57
- Works, last 5 years
- 4
- h-index
- 13
- Scientists listed
- 0
- Grants since 2016
- 10
Grants received
2025–2027 · research · R43
An AI-based empathic virtual companion to track changing health states in persons living with dementia
Mandy Salomon · PharmatrophiX (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Assessing a Novel Virtual Environment that Primes Individuals Living with AD/ADRD to Accomplish Activities of Daily Living.
Mandy Salomon · PharmatrophiX (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Assessing a Novel Virtual Environment that Primes Individuals Living with AD/ADRD to Accomplish Activities of Daily Living.
Mandy Salomon · PharmatrophiX (United States) · funded by National Institutes of Health
2020–2021 · research · R43
Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A
Arthur Thomas Suckow · PharmatrophiX (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Systemic Characterization of Novel Lipidated siRNA Conjugates
Arthur Thomas Suckow · PharmatrophiX (United States) · funded by National Institutes of Health
2019–2021 · research · R01
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
Manfred Windisch · PharmatrophiX (United States) · funded by National Institutes of Health
2016–2021 · research · R01
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
Manfred Windisch · PharmatrophiX (United States) · funded by National Institutes of Health
2016–2019 · research · R01
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
Manfred Windisch · PharmatrophiX (United States) · funded by National Institutes of Health
2016–2021 · research · R01
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
Manfred Windisch · PharmatrophiX (United States) · funded by National Institutes of Health
2016–2019 · research · R01
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
Manfred Windisch · PharmatrophiX (United States) · funded by National Institutes of Health
